Lipoxins as biomarkers of lupus and other inflammatory conditions

Lipids in Health and Disease

Undurti N Das¹ 

[1] UND Life Sciences, 13800 Fairhill Road, #321, Shaker Heights, OH 44120, USA

关键词: prostaglandins;    free radicals;    tumor necrosis factor;    cytokines;    autoimmunity;    maresins;    protectins;    resolvins;    lipoxins;    multiple sclerosis;    diabetes mellitus;    rheumatoid arthritis;    Lupus;   

Others  :  1212655
DOI  :  10.1186/1476-511X-10-76

 received in 2011-05-06, accepted in 2011-05-15,  发布年份 2011

【 摘 要 】

Inflammatory events persist in systemic lupus erythematosus (lupus) despite the use of anti-inflammatory (both steroidal and non-steroidal) and immunosuppressive drugs leading to delay in the healing/repair process and so tissue/organ damage continues. The continuation of inflammation in lupus could be attributed to failure of the resolution process due to deficiency of potent endogenous pro-resolution-inducing molecules such as lipoxin A₄ (LXA₄). It is likely that progression and flares of lupus and lupus nephritis are due to decreased formation and release of LXA₄. Hence, administration of LXA₄ and its analogues could be of benefit in lupus. Furthermore, plasma and urinary measurement of lipoxins may be used to predict prognosis and response to therapy. It is likely that lipoxins and other bioactive anti-inflammatory lipids such as resolvins, protectins, maresins and nitrolipids play a significant role in other auto-immune diseases such as rheumatoid arthritis, type 1 diabetes mellitus and multiple sclerosis and hence, could be of significant benefit in these diseases.

【 授权许可】

   
2011 Das; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Das UN: Clinical laboratory tools to diagnose inflammation. Advances in Clinical Chemistry 2006, 41:189-229.
• [2]Serhan CN: Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005, 73:141-162.
• [3]Claria J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995, 92:9475-9479.
• [4]Das UN: Essential fatty acids: Biochemistry, physiology, and pathology. Biotechnology J 2006, 1:420-439.
• [5]Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammatory signals. J Exp Med 2002, 196:1025-1037.
• [6]Das UN: Essential fatty acids- a review. Current Pharmaceutical Biotechnol 2006, 7:467-482.
• [7]Chiang N, Arita M, Serhan CN: Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essen Fatty Acids 2005, 73:163-177.
• [8]Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation signals in resolution. Nat Immunol 2001, 2:612-619.
• [9]Serhan CN, Maddox JF, Petasis NA, Akritopoulou-Zanze I, Papayianni A, Brady HR, Colgan SP, Madara JL: Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995, 34:14609-14615.
• [10]Zordoky BN, El-Kadi AO: Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010, 125:446-463.
• [11]Nithipatikom K, Gross GJ: Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther 2010, 15:112-119.
• [12]Campbell WB, Fleming I: Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch 2010, 459:881-895.
• [13]Arnold C, Konkel A, Fischer R, Schunck WH: Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep 2010, 62:536-547.
• [14]Kroetz DL, Zeldin DC: Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 2002, 13:273-283.
• [15]Gao L, Yin H, Milne GL, Porter NA, Morrow JD: Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem 2006, 281:14092-14099.
• [16]Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K: Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000, 192:1197-1204.
• [17]Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K, Chiang N: Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J Physiol Pharmacol 2000, 51(4 Pt 1):643-654.
• [18]Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronet K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG: Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003, 278:43807-43817.
• [19]Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN: Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003, 278:14677-14687.
• [20]Romano M, Luciotti G, Gangemi S, Marinucci F, Prontera C, D'Urbano E, Davì G: Urinary excretion of lipoxin A(4) and related compounds: development of new extraction techniques for lipoxins. Lab Invest 2002, 82:1253-1254.
• [21]Gangemi S, Luciotti G, D'Urbano E, Mallamace A, Santoro D, Bellinghieri G, Davi G, Romano M: Physical exercise increases urinary excretion of lipoxin A4 and related compounds. J Appl Physiol 2003, 94:2237-2240.
• [22]Gangemi S, Pescara L, D'Urbano E, Basile G, Nicita-Mauro V, Davì G, Romano M: Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. Exp Gerontol 2005, 40:612-614.
• [23]Wu SH, Liao PY, Yin PL, Zhang YM, Dong L: Inverse temporal changes of lipoxin A4 and leukotrienes in children with Henoch-Schönlein purpura. Prostaglandins Leukot Essent Fatty Acids 2009, 80:177-183.
• [24]Katoh T, Lakkis FG, Makita N, Badr KF: Co-regulated expression of glomerular 12/15-lipoxygenase and interleukin-4 mRNAs in rat nephrotoxic nephritis. Kidney Int 1994, 46:341-349.
• [25]Nassar GM, Badr KF: Role of leukotrienes and lipoxygenases in glomerular injury. Miner Electrolyte Metab 1995, 21:262-270.
• [26]Papayianni A, Serhan CN, Phillips ML, Rennke HG, Brady HR: Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int 1995, 47:1295-1302.
• [27]O'Meara YM, Brady HR: Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis. Kidney Int Suppl 1997, 58:S56-S61.
• [28]Wu SH, Liao PY, Yin PL, Zhang YM, Dong L: Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol 2009, 174:115-122.
• [29]Lattin JE, Schroder K, Su AI, Walker JR, Zhang J, Wiltshire T, Saijo K, Glass CK, Hume DA, Kellie S, Sweet MJ: Expression analysis of G Protein-Coupled Receptors in mouse macrophages. Immunome Res 2008, 4:5. BioMed Central Full Text
• [30]Milligan G, Stoddart LA, Brown AJ: G protein-coupled receptors for free fatty acids. Cell Signal 2006, 18:1360-1365.
• [31]Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM: GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
• [32]Suresh Y, Das UN: Protective action of arachidonic acid against alloxan-induced cytotoxicity and diabetes mellitus. Prostaglandins Leukotrienes Essential Fatty Acids 2001, 64:37-52.
• [33]Suresh Y, Das UN: Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: Effect of ω-6 fatty acids. Nutrition 2003, 19:93-114.
• [34]Suresh Y, Das UN: Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: Effect of ω-3 fatty acids. Nutrition 2003, 19:213-228.
• [35]Stene LC, Joner G, Norwegian Childhood Diabetes Study Group: Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003, 78:1128-1134.
• [36]Stene LC, Ulriksen J, Magnus P, Joner G: Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 2000, 43:1093-1098.
• [37]Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, Rialland M, Tessier C, Kang JX, Narce M: High Pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes, in press.
• [38]White PJ, Arita M, Taguchi R, Kang JX, Marette A: Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010, 59:3066-3073.
• [39]Das UN, Puskás LG: Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders. Lipids Health Dis 2009, 8:61. BioMed Central Full Text
• [40]Bonventre JV: Phospholipase A2 and signal transduction. J Am Soc Nephrol 1992, 3:128-150.
• [41]Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612-619.
• [42]Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR: Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000, 164:1663-1667.
• [43]Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999, 5:698-701.
• [44]Gilroy DW, Newson J, Sawmynaden P, Willoughby DA, Croxtall JD: A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J 2004, 18:489-498.
• [45]Cominelli F, Nast CC, Llerena R, Dinarello CA, Zipser RD: Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins. J Clin Invest 1990, 85:582-586.
• [46]Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC: Pro- and anti- inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats. Infect Immun 1991, 59:4436-4442.
• [47]Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R-L: Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196:1025-1037.
• [48]Croxtall JD, Choudhury Q, Tokumoto H, Flower RJ: Lipocortin-1 and the control of arachidonic acid release in cell signalling. Glucocorticoids inhibit G protein-dependent activation of cPLA2 activity. Biochem Pharmacol 1995, 50:465-474.